Metrovacesa S.A.

BME:MVC Aktierapport

Börsvärde: €1.8b

Metrovacesa Framtida tillväxt

Future kriterier kontrolleras 0/6

Metrovacesa förväntas öka intäkter och intäkter med 2.1% respektive 2.4% per år. EPS förväntas tillväxt med 1.7% per år. Avkastningen på eget kapital förväntas bli 6.2% om 3 år.

Viktig information

2.1%

Tillväxttakt i vinsten

1.71%

Tillväxttakt för EPS

Real Estate vinsttillväxt-0.6%
Intäkternas tillväxttakt2.4%
Framtida avkastning på eget kapital6.15%
Bevakning av analytiker

Low

Senast uppdaterad29 Apr 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside

Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.

MVC: Higher Required Return And Rich P/E Will Pressure Future Returns

Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.

MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns

Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.

MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance

Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.

MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View

Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.

MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance

Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.

MVC: Lower Discount Rate And High P/E Will Sustain Bearish View

Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.

MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook

Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).

MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis

Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.

MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook

Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.

Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate

Dec 20
Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate

MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects

Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.

Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?

Oct 02
Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?

Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Jul 25
Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

May 04
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?

Apr 12
Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?

Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
User avatar

Will Leverage Undersupplied Spanish Housing Market For Future Opportunities

High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.

Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?

Feb 07
Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?

An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued

Dec 13
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued

Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Is Metrovacesa (BME:MVC) Using Too Much Debt?

May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?

Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

When Should You Buy Metrovacesa S.A. (BME:MVC)?

Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Prognoser för vinst- och omsättningstillväxt

BME:MVC - Analytikernas framtida uppskattningar och tidigare finansiella data (EUR Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/2028757621781252
12/31/2027780641671842
12/31/2026745661831872
12/31/202570857217217N/A
9/30/202563227124124N/A
6/30/2025555-33131N/A
3/31/202560466363N/A
12/31/2024653169595N/A
9/30/2024651177575N/A
6/30/2024649185555N/A
3/31/2024616-15N/AN/AN/A
12/31/2023581-213232N/A
9/30/2023535-68N/AN/AN/A
6/30/2023430-719292N/A
3/31/2023454-38N/AN/AN/A
12/31/2022516-23211211N/A
9/30/202252925N/AN/AN/A
6/30/202257233227227N/A
3/31/202257531N/AN/AN/A
12/31/202151218139139N/A
9/30/2021413-71N/AN/AN/A
6/30/2021231-90-24-24N/A
3/31/2021138-160N/AN/AN/A
12/31/2020140-164-78-78N/A
9/30/2020164-87N/AN/AN/A
6/30/2020180-87-46-45N/A
3/31/2020214-6N/AN/AN/A
12/31/2019161-4-29-28N/A
9/30/20192060N/A-15N/A
6/30/20192205N/A18N/A
3/31/2019211-11N/A21N/A
12/31/2018190-9N/A35N/A
9/30/2018103-14N/A147N/A
6/30/201870-31N/A-19N/A
3/31/201834-34N/A-38N/A
12/31/201728-39N/A-27N/A
9/30/201729-55N/A-172N/A
12/31/201621-21N/A21N/A
12/31/20153664N/A-62N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: MVC s prognostiserade vinsttillväxt ( 2.1% per år) ligger under sparkvoten ( 2.6% ).

Resultat vs marknad: MVC s intäkter ( 2.1% per år) förväntas växa långsammare än marknaden för Spanish ( 10.8% per år).

Höga tillväxtresultat: MVC s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: MVC s intäkter ( 2.4% per år) förväntas växa långsammare än marknaden för Spanish ( 6.1% per år).

Hög tillväxtintäkter: MVC s intäkter ( 2.4% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: MVC s avkastning på eget kapital förväntas bli låg om 3 år ( 6.2 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/04 02:43
Aktiekurs vid dagens slut2026/05/04 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Metrovacesa S.A. bevakas av 22 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Ignacio RomeroBanco de Sabadell. S.A.
null nullBanco de Sabadell. S.A.
Mariano Miguel HidalgoBanco Santander